ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1229
-0,01%
Bitcoin
69.717,91
-0,59%
Brent Oil
81,53
-1,11%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neurobiological Technologies (MM) (NTII)

  7. Neurobiological Technologies (MM) (NTII) Notícias

NTII

Neurobiological (NTII)

Neurobiological Technologies (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTII
DataHoraFonteTítuloCódigoCompanhia
07/12/200917:18Edgar (US Regulatory)Current report filing (8-K)NASDAQ:NTIINeurobiological Technologies (MM)
07/12/200916:41Edgar (US Regulatory)-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)NASDAQ:NTIINeurobiological Technologies (MM)
23/11/200911:00PR Newswire (US)Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per ShareNASDAQ:NTII
16/11/200916:43Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:NTIINeurobiological Technologies (MM)
09/11/200919:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTIINeurobiological Technologies (MM)
28/10/200911:00PR Newswire (US)Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and DissolutionNASDAQ:NTII
26/10/200916:00Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTIINeurobiological Technologies (MM)
26/10/200915:59Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:NTIINeurobiological Technologies (MM)
23/10/200919:19Edgar (US Regulatory)Amended Statement of Beneficial Ownership (SC 13D/A)NASDAQ:NTIINeurobiological Technologies (MM)
19/10/200918:20PR Newswire (US)Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital MarketNASDAQ:NTII
22/09/200907:01Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:NTIINeurobiological Technologies (MM)
17/09/200918:00PR Newswire (US)Neurobiological Technologies Receives Nasdaq Closing Bid Price NotificationNASDAQ:NTII
08/09/200917:28Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)NASDAQ:NTIINeurobiological Technologies (MM)
31/08/200917:27PR Newswire (US)Neurobiological Technologies Announces Board Approval of Plan of Liquidation and DissolutionNASDAQ:NTIINeurobiological Technologies (MM)
31/08/200917:14Edgar (US Regulatory)Annual Report (10-K)NASDAQ:NTIINeurobiological Technologies (MM)
12/08/200909:30PR Newswire (US)Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical CenNASDAQ:NTIINeurobiological Technologies (MM)
01/06/200909:30PR Newswire (US)Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical ProgramNASDAQ:NTIINeurobiological Technologies (MM)
08/05/200908:00PR Newswire (US)Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial ResultsNASDAQ:NTIINeurobiological Technologies (MM)
01/05/200908:00PR Newswire (US)Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of MemantineNASDAQ:NTIINeurobiological Technologies (MM)
26/03/200908:30PR Newswire (US)Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of CompanyNASDAQ:NTIINeurobiological Technologies (MM)
18/02/200908:02Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:NTIINeurobiological Technologies (MM)
12/02/200919:30PR Newswire (US)Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial ResultsNASDAQ:NTIINeurobiological Technologies (MM)
05/02/200919:17Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:NTIINeurobiological Technologies (MM)
04/02/200910:00PR Newswire (US)Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEONASDAQ:NTIINeurobiological Technologies (MM)
23/01/200909:02Edgar (US Regulatory)Statement of Beneficial Ownership (SC 13D)NASDAQ:NTIINeurobiological Technologies (MM)
13/01/200910:30PR Newswire (US)Neurobiological Technologies Announces Suspension of Viprinex DevelopmentNASDAQ:NTIINeurobiological Technologies (MM)
17/12/200810:00PR Newswire (US)Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility AnalysisNASDAQ:NTIINeurobiological Technologies (MM)
16/12/200811:00PR Newswire (US)Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009NASDAQ:NTIINeurobiological Technologies (MM)
06/11/200809:30PR Newswire (US)Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial ResultsNASDAQ:NTIINeurobiological Technologies (MM)
05/11/200819:08Edgar (US Regulatory)Amended Securities Registration (section 12(g)) (8-A12G/A)NASDAQ:NTIINeurobiological Technologies (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTII

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
KRSA3
Kora Saude Participacoes... ON
BOV
BEEF3
MINERVA ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
COGN3
COGNA ON
BOV
IRBR3
IRB BRASIL ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados